UK re-in­ves­ti­gates Pfiz­er's eye-pop­ping price goug­ing on an epilep­sy drug

When a drug­mak­er rais­es the price of a drug in the US by more than 2,000% overnight, and with­out any par­tic­u­lar rea­son for that in­crease, noth­ing typ­i­cal­ly hap­pens to the com­pa­ny. No fines, no court or­ders, just busi­ness as usu­al.

Mar­tin Shkre­li’s decades-old an­ti-par­a­sitic drug Dara­prim was the per­fect ex­am­ple — mas­sive price spike on an old drug, lots of me­dia at­ten­tion, pub­lic out­cry, con­gres­sion­al com­mit­tees drag­ging his for­mer com­pa­ny through mul­ti­ple hear­ings, and at the end of it? Noth­ing hap­pened to the price or the com­pa­ny (un­til gener­ic com­pe­ti­tion came).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER